Royalty Pharma Plc (RPRX NASDAQ) stock market data APIs
$35.116
-0.31(-0.9%)
as of September 16, 2025
Try our APIs with
free plan!
Royalty Pharma Plc Financial Data Overview
Price chart is built with
Anychart
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prev. Close
35.116
Open
34.8079
High
35.9942
Low
34.7152
52 wk Range
23.5895-37.965
Market Cap
21 204 M
P/E Ratio
15.905
Shares Outstanding
432 M
Revenue
2 305 M
EPS
1.14
Dividends (Yield)
0.0237
Beta
0.574
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Royalty Pharma Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Royalty Pharma Plc data using free add-ons & libraries
Get Royalty Pharma Plc Fundamental Data
Royalty Pharma Plc Fundamental data includes:
- Net Revenue: 2 305 M
- EBITDA: 1 498 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: 1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Royalty Pharma Plc News
New
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing i...
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and wo...
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of t...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
Royalty Pharma plc On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
